MYR Pharmaceuticals gains conditional EC approval for Hepcludex

4 August 2020
hepatitis_liver_infection_credit_deposit_photos_large

Following a positive European Medicines Agency recommendation in May, the European Commission (EC) has now granted the conditional marketing authorization (CMA) for Hepcludex (bulevirtide), the lead product of German biotech MYR Pharmaceuticals.

Hepcludex has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology